CancerfromTNW | Health-Tech3 days agoUCB pays up to $2.2bn for Candid Therapeutics, doubling down on T-cell engagers in autoimmune diseaseUCB is acquiring Candid Therapeutics for $2bn to advance T-cell engagers for treating autoimmune diseases.
CancerfromBoston.com2 weeks agoEli Lilly to acquire Boston biotech Kelonia Therapy in $7 billion dealEli Lilly will acquire Kelonia Therapeutics for $7 billion to enhance its cancer treatment capabilities in Massachusetts.
Medicinefromenglish.elpais.com3 months agoThe pastry chef who patented an anti-cancer molecule that's been bought for over $8 billionPetosemtamab, co-invented by Eduard Batlle, achieved high response rates and complete remissions in head and neck cancer trials and was sold to Genmab.